Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Ankylosing Spondylitis
NCT00421915Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2002
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Etanercept with Placebo (2 arms). Primary endpoint: Assessment in Ankylosing Spondylitis 20% Response at 12 weeks. Started Mar 2002; status: completed.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00421915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421915.